Large gap with delayed quotes
Analysis date: 23.10.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 28.07.2026.
Quality
Strong
Strong
Three stars since 09.10.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 18.09.2026 at a price of 71.60.
Evaluation
Overvalued
Overvalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately overvalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 25.09.2026.
4wk Rel Perf
22.87%
22.87%
The four-week dividend-adjusted overperformance versus STOXX600 is 22.87%.
Risk
Middle
Middle
The stock has been on the moderate-sensitivity level since 06.03.2026.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.95%.
Mkt Cap in $bn
11.79
11.79
With a market capitalization >$8bn, BIOMERIEUX is considered a large-cap stock.
G/PE Ratio
0.77
0.77
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.9 indicates that investors must pay a premium for the estimated growth potential:
LT P/E
17.43
17.43
The estimated PE is for the year 2028.
LT Growth
12.21%
12.21%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
12
12
Over the last seven weeks, an average of 12 analysts provided earnings per share estimates.
Dividend Yield
1.27%
1.27%
The twelve month estimated dividend yield represents 22.14% of earnings forecasts.
Beta
53
53
For 1% of index variation, the stock varies on average by 0.53%.
Correlation
0.20
0.20
Stock movements are totally independent of index variations.
Value at Risk
21.41
21.41
The value at risk is estimated at EUR 21.41. The risk is therefore 24.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
16.03.2005
16.03.2005